Mod GRF 1-29 · DOSSIER

Mod GRF 1-29

Modified GRF (1-29) · CJC-1295 ohne DAC · Peptide · 29 AS
LEGAL DE · NOT APPROVEDEVIDENCE · PRECLINICAL2 STUDIESWADA · S2
FIG.01 — SIGNAL CHAIN
[D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]-GRF(1–29)-NH₂ · ~3367.9 Da
02

Mechanism of action

What Mod GRF 1-29 does in the body — step by step.

01

Mod GRF 1-29 is a synthetic GHRH analog based on the first 29 amino acids of growth hormone-releasing hormone.

02

Compared with sermorelin (unmodified GHRH 1-29), it carries four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that stabilise it against enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and increase receptor affinity.

03

Unlike CJC-1295 with DAC, Mod GRF 1-29 has no albumin-binding group — its half-life is therefore only about 30 minutes rather than several days.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
Mod GRF 1-29 emerged during the preclinical development of long-acting GHRH analogs (ConjuChem) as the backbone prior to DAC conjugation.
Mod GRF 1-29 emerged during the preclinical development of long-acting GHRH analogs (ConjuChem) as the backbone prior to DAC conjugation.
Independent controlled human studies of Mod GRF 1-29 as a final product are practically absent; its pharmacological characterisation derives largely from the context of CJC-1295 development and from general GHRH-analog pharmacology.
In the research community, Mod GRF 1-29 is discussed as a short-acting alternative to the DAC variant; robust clinical efficacy and safety data for this use are lacking.
04

Known risks

Without human data, safety statements are limited. What is known:

01
GH/IGF-1 overstimulation: insulin resistance, acromegaly-like symptoms possible with overdose
02
Theoretical cancer risk from elevated IGF-1 levels
03
Fluid retention and joint pain (known GH class effects)
04
No independent clinical long-term data
05
Legal risk: possession may be punishable under ADBG/DmMV
06
Product quality cannot be verified from unapproved sources
05

Cited studies

Chronological — links lead to the source.

2000
Synthetic GHRH analogs resistant to dipeptidyl peptidase IV cleavage: pharmacological characterization
PubMed 10923618 →
2006
Growth hormone-releasing factor (GRF) analogs with long-lasting activity: CJC-1295
PubMed 16822960 →
06

Frequently asked questions

What is Mod GRF 1-29?+

Mod GRF 1-29 is a synthetic GHRH analog based on the first 29 amino acids of growth hormone-releasing hormone.

What type of peptide is Mod GRF 1-29?+

Mod GRF 1-29 belongs to the GHRH analog class.

What is Mod GRF 1-29 used for?+

In research, Mod GRF 1-29 has primarily been investigated in the context of: Muscle growth, Anti-aging. These are research findings (evidence: preclinical), not proven benefits in humans and not a usage recommendation.

Is Mod GRF 1-29 legal in Germany?+

Mod GRF 1-29 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic. It is additionally relevant under the German Doping Agent Quantity Ordinance (DmMV).

Is Mod GRF 1-29 FDA-approved / legal in the US?+

No. Mod GRF 1-29 is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is Mod GRF 1-29 legal in Canada?+

No. Mod GRF 1-29 is not authorized by Health Canada and not intended for human consumption.

Where can I buy Mod GRF 1-29?+

Peptica sells nothing and names no sources. Mod GRF 1-29 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of Mod GRF 1-29?+

Peptica publishes no dosing. There are no approved dosing guidelines for Mod GRF 1-29; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is Mod GRF 1-29 banned in sport (WADA)?+

Yes. Mod GRF 1-29 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of Mod GRF 1-29?+

Documented risks include: GH/IGF-1 overstimulation: insulin resistance, acromegaly-like symptoms possible with overdose; Theoretical cancer risk from elevated IGF-1 levels. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is Mod GRF 1-29?+

The evidence is classified as “preclinical”. 2 studies are cited on this page.

What is the molecular weight of Mod GRF 1-29?+

Mod GRF 1-29 has a molar mass of about 3367.9 Da, with a plasma half-life of ~30 minutes.

Which peptides are related to Mod GRF 1-29?+

Closely related entries: CJC-1295, Ipamorelin, Sermorelin. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

As a GHRH analog, Mod GRF 1-29 is listed on the WADA Prohibited List (S2). It falls under the German Anti-Doping Act (ADBG) and is covered by the German Doping Agent Quantity Ordinance (DmMV) — possession of more than a minor quantity may be punishable under § 4 ADBG. Not approved as a medicine in the EU. Classified as not to be obtained.

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂N[D-Ala²,Gln,Ala¹,Leu²]-GRF(129)-NHCOOH
29
AMINO ACIDS
~3367.9
MOL. WEIGHT (Da)
~30 minutes
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01